Uncategorized

EnGeneIC and Singapore Institute of Advanced Medicine Holdings Forge Strategic Partnership to Revolutionise Cancer Treatment in Asia

EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted nanocell for cancer therapy has announced strategic partnerships with Singapore Institute of Advanced Medicine Holdings and Singapore Medical Incorporation.

EnGeneIC and Singapore Institute of Advanced Medicine Holdings Forge Strategic Partnership to Revolutionise Cancer Treatment in Asia Read More »

Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

Geron Corporation announced that the U.S. Food and Drug Administration has approved RYTELO™ for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating

Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia Read More »

Scroll to Top